*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 15, 2025 (the "**Prospectus**") issued by Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (翰思艾泰生物醫藥科技(武漢)股份有限公司) (the "**Company**").*

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such release, publication or distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the U.S. Securities Act or any states securities laws of the United States and may not be offered or sold within or to the United States or for the account or benefit of U.S. persons (as defined in Regulation S) except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in accordance with Regulation S.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

END OF STABILIZATION PERIOD, NO STABILIZATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

This announcement is made by the Company pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on Saturday, January 17, 2026, being the 30th day after the last day for lodging of applications under the Hong Kong Public Offering.

NO STABILIZATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

Reference is made to the announcement of the Company dated December 22, 2025. The Sponsor-Overall Coordinator (for itself and on behalf of the International Underwriters) confirmed that there had been no over-allocation of the Offer Shares under the International Offering. Therefore, the Over-allotment Option had not been exercised and the Over-allotment Option lapsed on Saturday, January 17, 2026. The Company was informed by the Stabilizing Manager that no stabilizing action was taken by the Stabilizing Manager or any person acting for it during the stabilization period.

PUBLIC FLOAT

Immediately after the end of the stabilization period, the Company complies and will continue to comply with the public float requirements under Rule 19A.13A of the Listing Rules, whereby at least 25% of the Company's total number of issued H Shares shall at all times be held by the public.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman

Hong Kong, January 23, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.